Central-boost Ablative Radiation Therapy for Large Tumors or Tumors Adjacent to Organs at Risk
Trial ID: NCT06427460
Interventional - Phase 2 - Recruiting
In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.
Conditions
Pancreatic Cancer
Interventions
Central-boost ablative dose delivered by stereotactic body radiation therapy
Eligibility
Inclusion criteria
- Aged 18-75 years.
Pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor.
Oligometastasis in the case of metastatic tumor
the shortest diameter ≥2cm or the distance from the tumor to the organs at risk less than 5mm
ECOG of 0 to 1 point
No abnormality in blood routine test, liver and kidney function test and coagulation test (White blood cell count ≥4.0×10^9/L, neutrophil count ≥2.0×10^9, hemoglobin level ≥100g/L, platelet count ≥100×10^9/L, ALT and AST level < 2.5 times the upper limit of normal, total bilirubin and creatinine level within the normal, international normalized ratio <2)
Exclusion criteria
- History of radiotherapy for the lesion
History of tumor within 5 years
ECOG ≥2 points
Significant abnormality in blood routine test, liver and kidney function test and coagulation test
Active inflammatory bowel disease in the case of pancreas or retroperitoneal tumor
Gastrointestinal bleeding or perforation within 6 months in the case of pancreas or retroperitoneal tumor